Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

B7148

Sigma-Aldrich

Buspirone hydrochloride

≥99% (TLC), powder, 5-HT1A serotonin receptor agonist

Sinonimo/i:

N-[4-[4-(2-Pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione hydrochloride

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C21H31N5O2 · HCl
Numero CAS:
33386-08-2
Peso molecolare:
421.96
Numero CE:
251-489-4
Numero MDL:
MFCD00078569
Codice UNSPSC:
12352200
ID PubChem:
24278079
NACRES:
NA.77

Nome del prodotto

Buspirone hydrochloride,

Stato

powder

Livello qualitativo

100

Ideatore

Bristol-Myers Squibb

Temperatura di conservazione

2-8°C

Stringa SMILE

Cl[H].O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)c4ncccn4

InChI

1S/C21H31N5O2.ClH/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20;/h5,8-9H,1-4,6-7,10-17H2;1H
RICLFGYGYQXUFH-UHFFFAOYSA-N

Informazioni sul gene

human ... HTR1A(3350)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Azioni biochim/fisiol

5-HT1A serotonin receptor agonist; anxiolytic.

Caratteristiche e vantaggi

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Skull and crossbones
GHS06

Avvertenze

Danger

Indicazioni di pericolo

H301

Classi di pericolo

Acute Tox. 3 Oral

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
BCCG0755
BCCC9648
BCBZ3793
BCBW1483
BCBV1732

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

Quipazine maleate salt

Sigma-Aldrich

Q1004

Quipazine maleate salt

Naratriptan hydrochloride ≥98% (HPLC)

Sigma-Aldrich

N1415

Naratriptan hydrochloride

(R)-(+)-8-Hydroxy-DPAT hydrobromide ≥98% (HPLC), solid

Sigma-Aldrich

H140

(R)-(+)-8-Hydroxy-DPAT hydrobromide

Ketanserin (+)-tartrate salt ≥97%, solid

Sigma-Aldrich

S006

Ketanserin (+)-tartrate salt

Trazodone hydrochloride ≥99% (HPLC), powder

Sigma-Aldrich

T6154

Trazodone hydrochloride

Desipramine hydrochloride ≥98% (TLC), powder

Sigma-Aldrich

D3900

Desipramine hydrochloride

E Meller et al.
Molecular pharmacology, 37(2), 231-237 (1990-02-01)
The irreversible receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was used to determine the relationship between receptor occupancy and response at central 5-hydroxytryptamine1A (5-HT1A) serotonin receptors mediating the inhibition of serotonin synthesis in rat cortex and hippocampus. Rats were treated with vehicle or
G Tunnicliff
Pharmacology & toxicology, 69(3), 149-156 (1991-09-01)
Buspirone has been available in the United States for over four years for the treatment of anxiety. It was anticipated this drug would offer certain advantages over the established benzodiazepines. In contrast to diazepam, early studies found no evidence for
Roy H Perlis et al.
The Journal of clinical psychiatry, 73(11), 1439-1442 (2012-10-13)
A subset of patients undergoing initial antidepressant treatment experience worsening of symptoms, including thoughts of suicide or suicidal behavior. The present study explores whether this subset of patients is also more likely to experience recurrence or worsening of these symptoms
Repurposing buspirone for drug addiction treatment.
Bernard Le Foll et al.
The international journal of neuropsychopharmacology, 16(2), 251-253 (2012-11-24)
Mohammad-Reza Mohammadi et al.
Acta medica Iranica, 50(11), 723-728 (2013-01-08)
A recent randomized clinical trial showed buspirone efficacy in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children. However, results from a recent multi-site controlled clinical trial of transdermal buspirone failed to separate it from placebo in a large sample of
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.